|
|
|
Insider
Information: |
Afeyan Noubar |
Relationship: |
Director, 10% Owner |
City: |
Lexington |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
8,070,025 |
|
Indirect Shares
|
111,880,829 |
|
|
Direct
Value |
$20,069,860 |
|
|
Indirect Value
|
$80,818,933 |
|
|
Total
Shares |
119,950,854 |
|
|
Total
Value |
$100,888,793 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
10
|
0
|
Stock
price went up :
|
3
|
0
|
Stock
price went down : |
7
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-22.5%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Color Kinetics Inc |
CLRK |
Director |
2005-10-03 |
83,062 |
2005-10-03 |
12,000 |
Premium* |
|
Agenus Inc |
AGEN |
Director |
2006-12-14 |
0 |
2006-12-14 |
0 |
Premium* |
|
Helicos Biosciences Corp |
HLCSQ |
Director, 10% Owner |
2009-09-18 |
0 |
2009-09-18 |
12,192,640 |
Premium* |
|
Receptos, Inc. |
RCPT |
10% Owner |
2013-11-18 |
1,693,551 |
|
0 |
Premium* |
|
DNIB Upwind Inc |
BIND |
Director, 10% Owner |
2013-09-25 |
0 |
2013-09-25 |
1,562,616 |
Premium* |
|
Bg Medicine, Inc. |
BGMD |
Director, 10% Owner |
2015-12-09 |
0 |
2015-12-09 |
1,286,274 |
Premium* |
|
Editas Medicine, Inc. |
EDIT |
10% Owner |
2016-02-08 |
3,964,256 |
2016-02-08 |
991,060 |
Premium* |
|
Selecta Biosciences Inc |
SELB |
10% Owner |
2016-06-27 |
0 |
2016-06-27 |
1,651,862 |
Premium* |
|
Kaleido Biosciences, Inc. |
KLDO |
10% Owner |
|
0 |
2021-02-08 |
14,907,627 |
Premium* |
|
Transmedics Group, Inc. |
TMDX |
10% Owner |
|
0 |
2019-10-29 |
120,595 |
Premium* |
|
Seres Therapeutics, Inc. |
MCRB |
10% Owner |
2019-06-18 |
15,141 |
2022-07-05 |
17,617,352 |
Premium* |
|
Moderna, Inc. |
MRNA |
|
2024-06-12 |
2,314,015 |
2024-06-12 |
4,632,149 |
Premium* |
|
Axcella Health Inc. |
AXLA |
10% Owner |
2020-05-18 |
0 |
2022-10-13 |
8,850,296 |
Premium* |
|
Evelo Biosciences Inc |
EVLO |
|
2020-06-29 |
0 |
2023-07-11 |
4,977,588 |
Premium* |
|
Codiak Biosciences, Inc. |
CDAK |
10% Owner |
|
0 |
2022-09-15 |
1,674,869 |
Premium* |
|
Foghorn Therapeutics Inc. |
FHTX |
10% Owner |
2020-10-27 |
0 |
2020-10-27 |
1,851,801 |
Premium* |
|
Sigilon Therapeutics, Inc. |
SGTX |
10% Owner |
2020-12-08 |
0 |
2023-08-11 |
0 |
Premium* |
|
Sana Biotechnology, Inc. |
SANA |
10% Owner |
2021-02-08 |
0 |
2023-09-13 |
581,695 |
Premium* |
|
Rubius Therapeutics, Inc. |
RUBY |
Director, 10% Owner |
2021-03-19 |
0 |
2021-03-19 |
17,253,519 |
Premium* |
|
Omega Therapeutics, Inc. |
OMGA |
Director, 10% Owner |
2021-08-03 |
0 |
2023-02-27 |
21,716,886 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
149 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
RCPT |
Receptos, Inc. |
10% Owner |
|
2013-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
114,285 |
|
- |
|
KLDO |
Kaleido Biosciences, Inc. |
Director |
|
2019-02-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,500,000 |
|
- |
|
TMDX |
Transmedics Group, Inc. |
10% Owner |
|
2019-05-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
483,021 |
|
- |
|
CDAK |
Codiak Biosciences, Inc. |
10% Owner |
|
2020-10-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
485,949 |
|
- |
|
CLRK |
Color Kinetics Inc |
Director |
|
2004-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
93,237 |
13,318 |
|
- |
|
CLRK |
Color Kinetics Inc |
Director |
|
2004-12-08 |
4 |
GA |
$0.00 |
$0 |
I/I |
12,000 |
12,000 |
|
- |
|
CLRK |
Color Kinetics Inc |
Director |
|
2004-12-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
81,237 |
|
- |
|
HLCSQ |
Helicos Biosciences Corp |
Director |
|
2009-09-18 |
4 |
B |
$0.00 |
$0 |
I/I |
242,931 |
12,192,640 |
2.17 |
- |
|
BIND |
DNIB Upwind Inc |
Director |
|
2013-09-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,542,616 |
1,542,616 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
10% Owner |
|
2016-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
991,060 |
991,060 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
10% Owner |
|
2016-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,964,256 |
3,964,256 |
0 |
- |
|
SELB |
Selecta Biosciences Inc |
10% Owner |
|
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
1,620,747 |
1,651,862 |
0 |
- |
|
KLDO |
Kaleido Biosciences, Inc. |
Director |
|
2019-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
11,070,951 |
1,910,972 |
0 |
- |
|
TMDX |
Transmedics Group, Inc. |
10% Owner |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
483,021 |
268,736 |
0 |
- |
|
TMDX |
Transmedics Group, Inc. |
10% Owner |
|
2019-05-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,690,579) |
0 |
0 |
- |
|
TMDX |
Transmedics Group, Inc. |
10% Owner |
|
2019-05-06 |
4 |
A |
$0.00 |
$0 |
I/I |
2,047,254 |
1,061,102 |
0 |
- |
|
TMDX |
Transmedics Group, Inc. |
10% Owner |
|
2019-10-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,840,191) |
0 |
0 |
- |
|
MRNA |
Moderna, Inc. |
Director |
|
2020-05-11 |
4 |
D |
$0.00 |
$0 |
I/I |
(12,281,179) |
0 |
0 |
- |
|
MRNA |
Moderna, Inc. |
Director |
|
2020-08-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(11,053,049) |
0 |
0 |
- |
|
CDAK |
Codiak Biosciences, Inc. |
10% Owner |
|
2020-10-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,956,354 |
978,177 |
0 |
- |
|
FHTX |
Foghorn Therapeutics Inc. |
10% Owner |
|
2020-10-27 |
4 |
A |
$0.00 |
$0 |
I/I |
12,524,120 |
1,801,801 |
0 |
- |
|
MCRB |
Seres Therapeutics, Inc. |
10% Owner |
|
2020-11-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(7,907,179) |
0 |
0 |
- |
|
SGTX |
Sigilon Therapeutics, Inc... |
10% Owner |
|
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
10,370,369 |
1,481,481 |
0 |
- |
|
SANA |
Sana Biotechnology, Inc. |
10% Owner |
|
2021-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
34,239,018 |
11,585,199 |
0 |
- |
|
MCRB |
Seres Therapeutics, Inc. |
10% Owner |
|
2021-05-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(295,171) |
2,962,963 |
0 |
- |
|
149 Records found
|
|
Page 1 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|